摘要
目的运用Meta分析评价西格列汀联合二甲双胍对肥胖2型糖尿病疗效和安全性。方法检索中国知识资源总库(CNKI)、中国学术期刊数据库(万方数据库)、中文科技期刊数据库(VIP),收集西格列汀联合二甲双胍对肥胖2型糖尿病的随机对照试验(RCT)。采用Rev Man 5.4统计软件进行Meta分析。结果共纳入10个研究,涵盖1156例患者。Meta分析结果显示,西格列汀联合二甲双胍试验组与二甲双胍对照组相比,能更有效降低糖化血红蛋白(HBA1C)[SMD=-0.71,95%CI(-0.95,-0.48),P<0.00001],空腹血糖(FBG)[SMD=-1.10,95%CI(-1.67,-0.54),P=0.0001],餐后2 h血糖(2hPG)[SMD=-0.9,95%CI(-1.22,-0.58),P<0.00001],胰岛素抵抗指数(HOMA-IR)[SMD=-0.79,95%CI(-1.35,-0.24),P=0.005],体重指数(BMI)[SMD=-0.37,95%CI(-0.68,-0.06),P=0.02],总胆固醇(TC)[SMD=-0.56,95%CI(-0.88,-0.24),P=0.0007],三酰甘油(TG)[SMD=-1.03,95%CI(-1.24,-0.82),P=0.00001]。结果显示,消化系统不良反应[OR=0.75,95%CI(0.46,1.24),P=0.27]两组间差异无统计学意义,试验组与对照组的消化系统不良反应发生情况相当。结论西格列汀联合二甲双胍治疗肥胖2型糖尿病疗效和安全性较高。
OBJECTIVE To evaluate the efficacy and safety of sitagliptin combined with metformin in the treatment of obese type 2 diabetes mellitus by using Meta analysis.METHODS Randomized controlled trials(RCTs)of sitagliptin combined with metformin on obese type 2 diabetes were collected from CNKI,Wanfang database and VIP database.Rev Man 5.4 statistical software was used for Meta analysis.RESULTS A total of 10 studies covering 1156 patients were included.Meta-analysis results showed that sitagliptin combined with metformin group were more effectively in reducing hemoglobin(HbA1 c)[SMD=-0.71,95%CI(-0.95,-0.48),P=0.00001]compared with metformin control group.Fasting blood glucose(FBG)[SMD=-1.10,95%CI(-1.67,-0.54),P=0.0001].Postprandial blood glucose(2 HPG)2 h[SMD=0.9,95%CI(1.22,0.58),P=0.00001].Indexes of insulin resistance(HOMA IR)[SMD=0.79,95%CI(1.35,0.24),P=0.005],Body mass index(BMI)[SMD=-0.37,95%CI(-0.68,-00.06),P=0.02],Total cholesterol(TC)[SMD=-0.56,95%CI(-0.88,-0.24),P=0.0007].Triacylglycerol(TG)[SMD=-1.03,95%CI(-1.24,-0.82),P=0.00001].ADR of digestive system[OR=0.75,95%CI(0.46,1.24),P=0.27],and the difference between the two groups was not statistically significant.The incidence of adverse reactions in digestive system was similar between the experimental group and the control group.CONCLUSION Sitagliptin combined with metformin is effective and safety in the treatment of obese type 2 diabetes.
作者
潘纯红
赵方允
PAN Chunhong;ZHAO Fangyun(Department of Pharmacy,Kunming First People’s Hospital,Calmette Hospital Affiliated to Kunming Medical University,Kunming,Yunnan 650000,China;Department of Pharmacy,Yan’an Hospital Affiliated to Kunming Medical University,Kunming,Yunnan 650051,China)
出处
《今日药学》
CAS
2021年第10期774-779,共6页
Pharmacy Today
基金
云南省高层次卫生计生技术人才培养经费资助(H-2019026)。
